Cooperative treatment effectiveness of ATR and HSP90 inhibition in Ewing's sarcoma cells.

ATM ATR Apoptosis Endoplasmic reticulum (ER) stress Ewing's sarcoma HSP90

Journal

Cell & bioscience
ISSN: 2045-3701
Titre abrégé: Cell Biosci
Pays: England
ID NLM: 101561195

Informations de publication

Date de publication:
20 Mar 2021
Historique:
received: 30 10 2020
accepted: 12 03 2021
entrez: 21 3 2021
pubmed: 22 3 2021
medline: 22 3 2021
Statut: epublish

Résumé

Ewing's sarcoma is an aggressive childhood malignancy whose outcome has not substantially improved over the last two decades. In this study, combination treatments of the HSP90 inhibitor AUY922 with either the ATR inhibitor VE821 or the ATM inhibitor KU55933 were investigated for their effectiveness in Ewing's sarcoma cells. Effects were determined in p53 wild-type and p53 null Ewing's sarcoma cell lines by flow cytometric analyses of cell death, mitochondrial depolarization and cell-cycle distribution as well as fluorescence and transmission electron microscopy. They were molecularly characterized by gene and protein expression profiling, and by quantitative whole proteome analysis. AUY922 alone induced DNA damage, apoptosis and ER stress, while reducing the abundance of DNA repair proteins. The combination of AUY922 with VE821 led to strong apoptosis induction independent of the cellular p53 status, yet based on different molecular mechanisms. p53 wild-type cells activated pro-apoptotic gene transcription and underwent mitochondria-mediated apoptosis, while p53 null cells accumulated higher levels of DNA damage, ER stress and autophagy, eventually leading to apoptosis. Impaired PI3K/AKT/mTOR signaling further contributed to the antineoplastic combination effects of AUY922 and VE821. In contrast, the combination of AUY922 with KU55933 did not produce a cooperative effect. Our study reveals that HSP90 and ATR inhibitor combination treatment may be an effective therapeutic approach for Ewing's sarcoma irrespective of the p53 status.

Identifiants

pubmed: 33743824
doi: 10.1186/s13578-021-00571-y
pii: 10.1186/s13578-021-00571-y
pmc: PMC7981928
doi:

Types de publication

Journal Article

Langues

eng

Pagination

57

Subventions

Organisme : DFG
ID : WA2627/1-1
Organisme : DFG
ID : WA2627/5-1
Organisme : Leibniz-Gemeinschaft
ID : SAW2014
Organisme : Leibniz-Gemeinschaft
ID : SAW2015
Organisme : German-Israeli Foundation for Scientific Research and Development
ID : I-1307-418.13/2015

Références

Mol Cell Biol. 2014 Feb;34(4):699-710
pubmed: 24324009
Mol Cell Oncol. 2018 May 29;5(4):e1465014
pubmed: 30250915
Biol Cell. 2011 Jun;103(6):271-85
pubmed: 21729000
Front Oncol. 2020 Jan 31;10:31
pubmed: 32082999
Cold Spring Harb Perspect Biol. 2013 Sep 01;5(9):
pubmed: 24003211
Anticancer Res. 2011 Apr;31(4):1197-204
pubmed: 21508365
Int J Cell Biol. 2013;2013:642853
pubmed: 24082883
Methods Mol Biol. 2017;1510:23-45
pubmed: 27761811
Mol Cancer Ther. 2013 Jun;12(6):831-43
pubmed: 23729400
Nucleic Acids Res. 2013 Jan;41(Database issue):D1063-9
pubmed: 23203882
J Cell Sci. 2015 Dec 1;128(23):4255-62
pubmed: 26567218
Science. 2007 May 25;316(5828):1160-6
pubmed: 17525332
Nat Biotechnol. 2014 Mar;32(3):223-6
pubmed: 24727771
Mol Cancer Ther. 2011 Jul;10(7):1194-206
pubmed: 21566061
J Exp Clin Cancer Res. 2018 Nov 9;37(1):272
pubmed: 30413206
Cancer Metastasis Rev. 2019 Dec;38(4):625-642
pubmed: 31970591
Sci Rep. 2016 Sep 09;6:32966
pubmed: 27611302
Pharmacol Ther. 2015 Apr;148:114-31
pubmed: 25435019
Nat Rev Mol Cell Biol. 2012 Jan 18;13(2):89-102
pubmed: 22251901
Int J Oncol. 2015 Jan;46(1):47-54
pubmed: 25351442
Nucleic Acids Res. 2017 Jan 4;45(D1):D1100-D1106
pubmed: 27924013
Cell Death Differ. 2012 Sep;19(9):1561-70
pubmed: 22460322
Pharmacol Ther. 2020 Jun;210:107518
pubmed: 32109490
Mol Oncol. 2014 Mar;8(2):323-36
pubmed: 24388362
Trends Cell Biol. 2020 Sep;30(9):672-675
pubmed: 32561138
Nat Rev Clin Oncol. 2020 Jan;17(1):33-48
pubmed: 31548601
EMBO J. 2017 Dec 15;36(24):3666-3681
pubmed: 29150431
Br J Cancer. 2010 May 25;102(11):1578-91
pubmed: 20502461
Genes Dev. 2016 Jul 1;30(13):1492-502
pubmed: 27401552
Nat Rev Mol Cell Biol. 2020 Apr;21(4):183-203
pubmed: 31937935
Cell Commun Signal. 2018 Sep 12;16(1):57
pubmed: 30208972
Immunity. 2016 Nov 15;45(5):963-973
pubmed: 27851925
Cancer Metastasis Rev. 2009 Jun;28(1-2):225-32
pubmed: 19153668
Methods Mol Biol. 2015;1292:3-18
pubmed: 25804744
Autophagy. 2016;12(1):1-222
pubmed: 26799652
Mol Neurobiol. 2018 Dec;55(12):8765-8787
pubmed: 29594942
Mol Cancer Ther. 2016 Mar;15(3):448-59
pubmed: 26832792
Front Neurosci. 2018 Feb 27;12:116
pubmed: 29535606
Cell Death Differ. 2017 May;24(5):944-950
pubmed: 28409774
Nat Rev Dis Primers. 2018 Jul 5;4(1):5
pubmed: 29977059
Invest New Drugs. 2018 Jun;36(3):396-406
pubmed: 29150734
Biochem Pharmacol. 2009 Jul 15;78(2):142-52
pubmed: 19464431
Mol Cancer Res. 2021 Feb;19(2):192-206
pubmed: 33020173
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Oncotarget. 2017 Jan 17;8(3):4079-4095
pubmed: 27863422
Annu Rev Immunol. 2018 Apr 26;36:489-517
pubmed: 29400998
Mol Cell Proteomics. 2012 Mar;11(3):M111.014654
pubmed: 22167270
Oncogene. 2017 Jul 13;36(28):3943-3956
pubmed: 28288132
Oncotarget. 2016 Oct 4;7(40):65540-65552
pubmed: 27608846
Methods Enzymol. 2011;490:71-92
pubmed: 21266244
Biochem Pharmacol. 2014 Feb 1;87(3):445-55
pubmed: 24291777
Recent Pat Anticancer Drug Discov. 2014 Jan;9(1):1-20
pubmed: 23312026
Nat Commun. 2016 Jun 24;7:11807
pubmed: 27339797
Nat Rev Cancer. 2020 Aug;20(8):471-480
pubmed: 32404993
N Engl J Med. 2021 Jan 14;384(2):154-164
pubmed: 33497548
Oncotarget. 2016 Sep 13;7(37):58759-58767
pubmed: 27577084
Biochim Biophys Acta. 2013 Jun;1833(6):1356-66
pubmed: 23485394
Mol Cancer Res. 2020 Jan;18(1):91-104
pubmed: 31649026
Cold Spring Harb Perspect Med. 2016 May 02;6(5):
pubmed: 27048304
Nat Rev Cancer. 2014 May;14(5):359-70
pubmed: 24739573
Int J Mol Sci. 2018 May 30;19(6):
pubmed: 29848965
J Biol Chem. 2018 Apr 13;293(15):5414-5424
pubmed: 29247007
J Cancer Res Clin Oncol. 2020 Nov;146(11):2871-2883
pubmed: 32770382
J Cell Biol. 1965 May;25:407-8
pubmed: 14287192
Cancer Discov. 2014 Nov;4(11):1326-41
pubmed: 25186949
Cell Mol Biol Lett. 2016 Sep 20;21:18
pubmed: 28536620
Cancer Discov. 2014 Nov;4(11):1342-53
pubmed: 25223734
Eur J Cancer. 2015 May;51(7):841-51
pubmed: 25801700
Curr Protoc Cell Biol. 2001 May;Chapter 4:Unit 4.4
pubmed: 18228364
Science. 2014 Jul 4;345(6192):98-101
pubmed: 24994655

Auteurs

Christian Marx (C)

Leibniz Institute On Aging - Fritz Lipmann Institute (FLI), Jena, Germany.

Marc U Schaarschmidt (MU)

Department of Pediatric Hematology and Oncology, Children's Clinic, Jena University Hospital, Jena, Germany.
Research Center Lobeda, Jena University Hospital, Jena, Germany.

Joanna Kirkpatrick (J)

Leibniz Institute On Aging - Fritz Lipmann Institute (FLI), Jena, Germany.
Francis Crick Institute, London, UK.

Lisa Marx-Blümel (L)

Department of Pediatric Hematology and Oncology, Children's Clinic, Jena University Hospital, Jena, Germany.
Research Center Lobeda, Jena University Hospital, Jena, Germany.

Melisa Halilovic (M)

Leibniz Institute On Aging - Fritz Lipmann Institute (FLI), Jena, Germany.

Martin Westermann (M)

Electron Microscopy Center, Jena University Hospital, Jena, Germany.

Doerte Hoelzer (D)

Department of Human Nutrition, Institute of Nutrition, Friedrich Schiller University Jena, Jena, Germany.
Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany.

Felix B Meyer (FB)

Department of Human Nutrition, Institute of Nutrition, Friedrich Schiller University Jena, Jena, Germany.

Yibo Geng (Y)

Leibniz Institute On Aging - Fritz Lipmann Institute (FLI), Jena, Germany.
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Katrin Buder (K)

Leibniz Institute On Aging - Fritz Lipmann Institute (FLI), Jena, Germany.

Hauke M Schadwinkel (HM)

Department of Pediatric Hematology and Oncology, Children's Clinic, Jena University Hospital, Jena, Germany.
Research Center Lobeda, Jena University Hospital, Jena, Germany.

Kanstantsin Siniuk (K)

Leibniz Institute On Aging - Fritz Lipmann Institute (FLI), Jena, Germany.

Sabine Becker (S)

Department of Pediatric Hematology and Oncology, Children's Clinic, Jena University Hospital, Jena, Germany.
Research Center Lobeda, Jena University Hospital, Jena, Germany.

René Thierbach (R)

Department of Human Nutrition, Institute of Nutrition, Friedrich Schiller University Jena, Jena, Germany.

James F Beck (JF)

Department of Pediatric Hematology and Oncology, Children's Clinic, Jena University Hospital, Jena, Germany.

Jürgen Sonnemann (J)

Department of Pediatric Hematology and Oncology, Children's Clinic, Jena University Hospital, Jena, Germany. juergen.sonnemann@med.uni-jena.de.
Research Center Lobeda, Jena University Hospital, Jena, Germany. juergen.sonnemann@med.uni-jena.de.
Klinik Für Kinder- Und Jugendmedizin, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany. juergen.sonnemann@med.uni-jena.de.

Zhao-Qi Wang (ZQ)

Leibniz Institute On Aging - Fritz Lipmann Institute (FLI), Jena, Germany.
Faculty of Biology and Pharmacy, Friedrich Schiller University of Jena, Jena, Germany.

Classifications MeSH